These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 34486907)
21. Decreased hearing after combined modality therapy for head and neck cancer. Pearson SE; Meyer AC; Adams GL; Ondrey FG Am J Otolaryngol; 2006; 27(2):76-80. PubMed ID: 16500467 [TBL] [Abstract][Full Text] [Related]
22. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer. Madasu R; Ruckenstein MJ; Leake F; Steere E; Robbins KT Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250 [TBL] [Abstract][Full Text] [Related]
23. Sensorineural hearing loss after radiotherapy for head and neck tumors: a prospective study of the effect of radiation. Yilmaz YF; Aytas FI; Akdogan O; Sari K; Savas ZG; Titiz A; Tumoz M; Unal A Otol Neurotol; 2008 Jun; 29(4):461-3. PubMed ID: 18520582 [TBL] [Abstract][Full Text] [Related]
24. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425 [TBL] [Abstract][Full Text] [Related]
26. Risk Profiles for Sensorineural Hearing Loss in Patients with Head and Neck Cancer Receiving Cisplatin-based Chemoradiation. Shorter P; Harden F; Owen R; Panizza B; Burmeister B; Sommerville J; Mengersen K; Foote M J Med Imaging Radiat Sci; 2017 Mar; 48(1):61-67. PubMed ID: 31047212 [TBL] [Abstract][Full Text] [Related]
27. Factors Affecting Permanent Sensorineural Hearing Loss and Bone Conduction in Patients After Receiving Radiotherapy to the Head and Neck Region. Yücel B; Erdiş E; Bahar S; Akkaş Atasever E; Celasun MG; Altuntaş EE Turk Arch Otorhinolaryngol; 2022 Dec; 60(4):212-219. PubMed ID: 37456600 [TBL] [Abstract][Full Text] [Related]
28. Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy. Niemensivu R; Saarilahti K; Ylikoski J; Aarnisalo A; Mäkitie AA Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2509-14. PubMed ID: 26685859 [TBL] [Abstract][Full Text] [Related]
29. Audiological findings in patients treated with radio- and concomitant chemotherapy for head and neck tumors. Dell'Aringa AH; Isaac ML; Arruda GV; Esteves MC; Dell'aringa AR; Júnior JL; Rodrigues AF Radiat Oncol; 2009 Nov; 4():53. PubMed ID: 19912669 [TBL] [Abstract][Full Text] [Related]
30. Sensorineural hearing loss after concurrent chemoradiotherapy in nasopharyngeal cancer patients. Petsuksiri J; Sermsree A; Thephamongkhol K; Keskool P; Thongyai K; Chansilpa Y; Pattaranutaporn P Radiat Oncol; 2011 Feb; 6():19. PubMed ID: 21333025 [TBL] [Abstract][Full Text] [Related]
31. Validation of Hearing Loss Prediction Tool for Cisplatin Chemotherapy and Radiation in Head and Neck Cancer Treatment. Deutsch BC; Collopy C; Kallogjeri D; Piccirillo JF JAMA Otolaryngol Head Neck Surg; 2021 Feb; 147(2):182-189. PubMed ID: 33300954 [TBL] [Abstract][Full Text] [Related]
32. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer. Caballero M; Mackers P; Reig O; Buxo E; Navarrete P; Blanch JL; Grau JJ Oncology; 2017; 93(2):75-82. PubMed ID: 28511189 [TBL] [Abstract][Full Text] [Related]
33. Hearing Loss After Cisplatin-based Chemoradiotherapy for Locally Advanced Head and Neck Cancer: A Prospective Single-institution Study. Musio D; DE Vincentiis M; D'Urso P; Musacchio A; Maiuri V; Zaccaro L; Ralli M; Marchetti C; Turchetta R; Tombolini V; DE Felice F Anticancer Res; 2022 Jun; 42(6):3003-3009. PubMed ID: 35641273 [TBL] [Abstract][Full Text] [Related]
34. Characteristics of radiation-induced sensorineural hearing loss in head and neck cancer: a systematic review. Mujica-Mota M; Waissbluth S; Daniel SJ Head Neck; 2013 Nov; 35(11):1662-8. PubMed ID: 23280686 [TBL] [Abstract][Full Text] [Related]
35. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children. Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818 [TBL] [Abstract][Full Text] [Related]
36. Dosimetric parameters associated with conductive or sensorineural hearing loss 5 years after intensity-modulated radiation therapy in nasopharyngeal carcinoma. Zhu W; Chen F; Li J; Wang W; Zhang H; Yang G; Zou L; Zhu Y; Yuan W; Ding H; Song X; Wang S Acta Otolaryngol; 2019 Mar; 139(3):263-268. PubMed ID: 30870056 [TBL] [Abstract][Full Text] [Related]
37. Hearing Loss Risk in Pediatric Patients Treated with Cranial Irradiation and Cisplatin-Based Chemotherapy. Cohen-Cutler S; Wong K; Mena V; Sianto K; Wright MA; Olch A; Orgel E Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1488-1495. PubMed ID: 33677052 [TBL] [Abstract][Full Text] [Related]
38. Cochlea sparing effects of intensity modulated radiation therapy in head and neck cancers patients: a long-term follow-up study. Theunissen EA; Zuur CL; Yurda ML; van der Baan S; Kornman AF; de Boer JP; Balm AJ; Rasch CR; Dreschler WA J Otolaryngol Head Neck Surg; 2014 Aug; 43(1):30. PubMed ID: 25095702 [TBL] [Abstract][Full Text] [Related]
39. Sensorineural hearing loss following induction chemotherapy plus concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma. Atchariyasathian V; Pruegsanusak K; Wongsriwattanakul S J Laryngol Otol; 2015 Aug; 129(8):767-72. PubMed ID: 26112091 [TBL] [Abstract][Full Text] [Related]
40. Age-corrected hearing loss after chemoradiation in cervical cancer patients. Marnitz S; Schermeyer L; Dommerich S; Köhler C; Olze H; Budach V; Martus P Strahlenther Onkol; 2018 Nov; 194(11):1039-1048. PubMed ID: 30120496 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]